| Formulary Chapter 13: Skin - Full Chapter
|
| Notes: |
Please note: Silk garments are non-formulary. |
|
| Details... |
| 13.05.02 |
Preparations for psoriasis |
|
|
|
|
| 13.05.02 |
Topical preparations for psoriasis |
|
|
Calcipotriol 50mcg/g ointment
|
Formulary
|
|
|
|
Calcipotriol 50mcg/ml scalp application
|
Formulary
|
££££
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet Gel®)
|
Formulary
|
Scalp psoriasis: usual duration of treatment is 4 weeks
Mild to moderate plaque psoriasis, apply once daily to max. 30% of body surface (max. 15 g daily) for 8 weeks
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet ointment ®)
|
Formulary
|
4 weeks therapy then assess
Maximum 15g per day or 100g per week.
Step down to calcipotrol oint as per NICE CG153
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g (Enstilar®)
|
Formulary
|
Cutaneous foam formulation
The recommended treatment period is 4 weeks
Maximum 15g per day
Excipients include liquid paraffin and butane- Extremely flammable aerosol
|
|
|
Calcitriol 3micrograms/g (Silkis®)
|
Formulary
|
- Specialist recommendation
- For delicate areas,face and flexures
|
|
|
Coal tar lotion 5% (Exorex®)
|
Formulary
|
|
|
|
Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% (Polytar Emollient®)
|
Formulary
|
contains peanut oil
|
|
|
Dithranol (Dithrocream®)
|
Formulary
|
- All Strengths. Specialist Recommendation
|
|
|
Sebco®
|
Formulary
|
|
|
|
Tars - bath preparations (Psoriderm emulsion®)
|
Formulary
|
|
 Birmingham and Solihull CCG Policy for items which should not be prescribed in primary care
NHS Clinical Commissioners Items which should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.05.02 |
Oral retinoids for psoriasis |
|
|
| .... |
| Non Formulary Items |
Coal Tar 10% (Carbo-Dome®)
|
Non Formulary
|
|
|
|
Coal Tar in Lassars Paste
|
Non Formulary
|
|
|
|
Coal Tar in Unguentum M
|
Non Formulary
|
|
|
|
Dithranol (Micanol®)
|
Non Formulary
|
|
|
|
Dithranol (Psorin®)
|
Non Formulary
|
|
|
|
Dithranol Ointment BP
|
Non Formulary
|
|
|
|
Dithranol Paste BP
|
Non Formulary
|
|
|
|
Salicylic Acid 3% w/w, Sulphur 3% w/w in Aqueous Cream
|
Non Formulary
|
|
|
|
Salicylic Acid in White Soft Paraffin
|
Non Formulary
|
|
|
|
Tacalcitol (Curatoderm®)
|
Non Formulary
|
|
|
|
Tars
|
Non Formulary
|
|
|
|
Tars (Clinitar®)
|
Non Formulary
|
|
|
|
Tars (Cocois®)
|
Non Formulary
|
|
|
|
Tars (Psoriderm®)
|
Non Formulary
|
|
|
|
Tars (Zinc and Coal Tar Paste®)
|
Non Formulary
|
|
|
|
Tars - bath preparations
|
Non Formulary
|
|
Birmingham and Solihull CCG Policy for items which should not be prescribed in primary care
NHS Clinical Commissioners Items which should not routinely be prescribed in primary care: Guidance for CCGs
|
Tars - bath preparations (Pinetarsol®)
|
Non Formulary
|
|
Birmingham and Solihull CCG Policy for items which should not be prescribed in primary care
NHS Clinical Commissioners Items which should not routinely be prescribed in primary care: Guidance for CCGs
|
Tazarotene 0.05% (Zorac®)
|
Non Formulary
|
|
|
|
Zinc and Salicylic Acid Paste BP
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Prescribing in children
The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.
The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
|
|
Medicines suitable for routine use within primary care. Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians. |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Medicines for initiation and maintenance prescribing by Specialists only. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Positive NICE TA and/or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
The term 'Specialist' refers to Consultants, General Practitioners and Independant Prescribers with a Specialist Interest. |
|
|
|
